Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Placebo-Controlled, Single-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB680 in Healthy Volunteers

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Single-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB680 in Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2019

At a glance

  • Drugs AB-680 (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Arcus Biosciences
  • Most Recent Events

    • 21 Dec 2018 Planned number of patients changed from 16 to 32.
    • 21 Dec 2018 Planned End Date changed from 18 Mar 2019 to 28 May 2019.
    • 21 Dec 2018 Planned primary completion date changed from 18 Mar 2019 to 28 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top